OncoMatch/Clinical Trials/NCT04901234
Adaptive RadioTherapy for OroPharynx Cancer
Is NCT04901234 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for oropharynx cancer.
This is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to systematic mid-treatment MRI-based radiotherapy adaptation vs. standard of care. The primary objective is to compare patient-rated dysphagia (as assessed by the MD Anderson Dysphagia Inventory composite score at 6 months post-treatment in patients undergoing routine mid-treatment MR-guided radiotherapy adaptation vs. in patients receiving the current standard of care.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: irradiation of the head and neck region
Exception: excluding superficial radiation therapy for non-melanomatous skin cancer
Previous irradiation of the head and neck (HNC) region, excluding superficial radiation therapy for non-melanomatous skin cancer
Cannot have received: surgery of the head and neck region
Exception: except for incisional or excisional biopsies
Previous surgery of the HNC region (except for incisional or excisional biopsies)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04901234 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior irradiation of the head and neck region, surgery of the head and neck region disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages